The use of benzodiazepines could be a protective factor for community-acquired pneumonia (CAP) in ≤ 60 -year-old subjects

We have read with interest the study of Obiora *et al*¹ regarding the effect of benzodiazepines (BZs) on the risk of community-acquired pneumonia (CAP). It is concluded that the use of BZs was associated with an increased risk for CAP and CAP-related mortality. However, the effect of BZs in patients with CAP is still a matter of debate. We would like to contribute to this unsolved question, with new data from a previously published population-based case-control study carried out in a sample of 2662 subjects (1336 CAP patients and 1326 controls).² In fact, not only the use of BZs was not statistically associated with CAP in the overall study population, but also a protective effect for CAP was observed in the subgroup of patients aged 60 years or younger (see table 1), with an OR of 0.54 ($p=0.012$) in the bivariate analysis and an OR of 0.53 (95% CI 0.31 to 0.91) in the multivariate analysis after adjusting for asthma, chronic

► <http://dx.doi.org/10.1136/thoraxjnl-2013-203701>

Thorax 2013;**68**:964–965.
doi:10.1136/thoraxjnl-2013-203634

REFERENCES

- Obiora E, Hubbard R, Sanders RD, *et al.* The impact of benzodiazepines on occurrence of pneumonia and mortality from pneumonia: a nested case-control and survival analysis in a population-based cohort. *Thorax* 2013;**68**:163–70.
- Almirall J, Bolibar I, Serra-Prat M, *et al.* New evidence of risk factors for community-acquired pneumonia: a population-based study. *Eur Respir J* 2008;**31**:1274–84.
- Almirall J, Bolibar I, Balanzó X, *et al.* Risk factor for community acquired pneumonia in adults: a population-based case-control study. *Eur Resp J* 1999;**13**:349–55.
- Iqbal U, Syed-Abdul S, Nguyen PA, *et al.* The use of benzodiazepines is not associated with community-acquired pneumonia. *Thorax* Published Online First: 3 February 2013. doi:10.1136/thoraxjnl-2013-203211
- Gaillard JM. Benzodiazepines and GABA-ergic transmission. In: Kryger MH, Toth T, Dement WC, eds. *Principles and practice of sleep medicine*. Philadelphia, PA: WB Saunders, 1989;213–18.

Table 1 Effect of benzodiazepines on community-acquired pneumonia

Benzodiazepines use	Controls (n=1326)	Cases (n=1336)	p	OR (CI 95%)
Overall sample	121 (9.2%)	111 (8.3%)	0.455	0.90 (0.69 to 1.18)
≤60 years old	46 (7.0%)	26 (3.9%)	0.012	0.54 (0.33 to 0.88)
>60 years old	75 (11.5%)	85 (12.9%)	0.428	1.14 (0.82 to 1.59)
<i>Only ≤60-year-old subjects</i>				
<i>Half-life</i>				
No use of BZ	614 (93.0%)	648 (96.3%)		1
Low	4 (0.6%)	1 (0.1%)	0.024	0.24 (0.03 to 2.13)
Medium-high	42 (6.4%)	24 (3.6%)		0.54 (0.32 to 0.91)
<i>Hypnotic power</i>				
No use of BZ	614 (93.0%)	648 (96.3%)		1
Low	10 (1.5%)	11 (1.6%)	0.007	1.04 (0.44 to 2.47)
Medium-high	35 (5.3%)	14 (2.1%)		0.38 (0.20 to 0.71)
<i>Miorelaxant power</i>				
No use of BZ	614 (93.0%)	648 (96.3%)		1
Low	23 (3.5%)	14 (2.1%)	0.036	0.58 (0.29 to 1.13)
Medium-high	22 (3.3%)	11 (1.6%)		0.47 (0.23 to 0.99)
<i>Anxylitic power</i>				
No use of BZ	614 (93.0%)	648 (96.3%)		1
Low	2 (0.3%)	1 (0.1%)	0.039	0.47 (0.04 to 5.24)
Medium-high	43 (6.5%)	24 (3.6%)		0.53 (0.32 to 0.88)

BZ, Benzodiazepines.

bronchitis, upper airway infection in the last month, hospitalisation in the last 5 years, temperature change, educational level and flu vaccination. In subjects older than 60 years of age, the protective effect of BZs disappeared. Only in the ≤60-year-old age group, we observed a protective effect of BZs with medium or high half-life, hypnotic, miorelaxant and anxylitic power (see table 1). These findings were also consistent with a previous study of our group³ and results recently reported by Iqbal *et al.*⁴ The study of Obiora *et al.*¹ was based on data from a large database which could have, as a main limitation, a misclassification both in disease codification and drug exposure. This misclassification could be particularly relevant in patients with CAP without radiological and follow-up confirmation of pneumonia. Strengths of our study² include the confirmation of CAP by two chest radiographs, the first when the diagnosis was suspected, and the second, 1 month later, as well as assessment of drug exposure by a general practitioner or a nurse at the patients' home during administration of a questionnaire. Because conclusive studies regarding the effect of BZs on the immune system are lacking, it may be suggested that BZs could act inhibiting the rapid eye movement (REM) phase of sleep, preventing bronchial aspirations associated with this phase of sleep.⁵ The protective effect of BZ may

disappear in older subjects with immunosenescence and a high prevalence of comorbidities that may predispose to pneumonia (eg, oropharyngeal dysphagia). The role of BZs in CAP needs to be better studied.

Jordi Almirall,¹ Mateu Serra-Prat,²
Francisco Baron,³ Elisabet Palomera,²
Ignasi Bolibar⁴

¹Intensive Care Unit, Hospital de Mataró, Mataró, Barcelona, Spain, CIBERES Spain

²Research Unit, Consorci Sanitari del Maresme, Mataró, Barcelona, Spain

³Psychiatric Department, Hospital de Mataró, Mataró, Barcelona, Spain

⁴Department of Clinical Epidemiology and Public Health, Hospital de la Santa Creu i de Sant Pau, Barcelona, Spain

Correspondence to Dr Jordi Almirall, Intensive Care Unit, Hospital de Mataró, Carretera de Cirera s/n, Mataró, Barcelona 08304, Spain; jalmirall@csdm.cat

Contributors JA, MSP and IB have designed the study, contributed in the field work and write the manuscript. FB has helped in benzodiazepine classification and data interpretation. EP has performed the statistical analysis.

Funding This study is supported by FIS ISCIII (grant number FIS P1021151 ISCIII).

Competing interests None.

Ethics approval Institutional review board of CSdM.

Provenance and peer review Not commissioned; internally peer reviewed.

To cite Almirall J, Serra-Prat M, Baron F, *et al.* *Thorax* 2013;**68**:964–965.

Received 27 March 2013

Accepted 10 April 2013